Drug Profile
MB 66
Alternative Names: HIV/HSV microbicide - Mapp; Mapp 66; MB-66Latest Information Update: 28 Jun 2022
Price :
$50
*
At a glance
- Originator Mapp Biopharmaceutical
- Developer Boston University; Integrated Preclinical/Clinical Program for HIV Topical Microbicides Consortium; Mapp Biopharmaceutical; The Miriam Hospital
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action HIV envelope protein gp120 inhibitors; HIV envelope protein gp41 inhibitors; HIV fusion inhibitors; Immunomodulators; Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Herpes simplex virus infections; HIV infections
Most Recent Events
- 28 Jun 2022 No recent reports of development identified for phase-I development in Herpes-simplex-virus-infections(Prevention) in USA (Vaginal, Film)
- 28 Jun 2022 No recent reports of development identified for phase-I development in HIV-infections in USA (Vaginal, Film)
- 23 Jun 2020 MB 66 is still in phase I development for HIV-infections and Herpes simplex virus infections (Mapp Biopharmaceutical pipeline, June 2020)